It can facilitate cell growth, inhibit cell cycle arrest and apoptosis, promote migration and invasion, and increase regulatory T cell (Treg) while decrease CD8+ T cell infiltration in NSCLC tumors by modulating the LINC00301/enhancer of zeste homolog 2 (EZH2)/ELL protein-associated factor 2 (EAF2)/von Hippel–Lindau (pVHL)/hypoxia-inducible factor 1 subunit alpha (HIF1α) axis in the nucleus and the LINC00301/miR-1276/HIF1α pathway in the cytoplasm. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.